8-K: PetVivo Holdings Secures $3 Million in Latest Tranche of $5 Million Equity Financing

PetVivo Holdings, Inc. announced the receipt of $3 million from a partial exercise of a purchase option, bringing the total equity financing received to date to $4 million out of a $5 million Series B Convertible Preferred Stock offering.

Summary

• PetVivo Holdings, Inc. received $3,000,000 on June 20, 2025, from a partial exercise of a purchase option granted to an investor.
• This payment is part of a larger $5,000,000 equity financing offering for Five Million shares of Series B Convertible Preferred Stock.
• The company has now received an aggregate total of $4,000,000 from this offering, including a prior $1,000,000.
• An additional $1,000,000 from the purchase option remains for exercise at the investor's discretion and is anticipated to be received by June 26, 2025.
• The Series B Convertible Preferred Stock is priced at $1.00 per share and is convertible into common stock at a 1:1 ratio.
• The offering was conducted as an unregistered sale pursuant to Section 4(a)(2) of the Securities Act of 1933, targeting accredited investors.
• The Series B Preferred Stock includes voting rights equal to the common stock it's convertible into, a company call option after two years at $1.15 per share, and a 10% annual dividend paid quarterly in common stock.
• Proceeds from the offering are primarily intended for commercialization of lead products Spryng with OsteoCushion Technology and PrecisePRP, financing clinical trials, and funding working capital and general corporate purposes.

Sentiment

Score: 6

Explanation: The document reports a successful capital raise, which is positive for funding operations and strategic initiatives. However, it also explicitly highlights the speculative nature of the investment, high degree of risk, and immediate substantial dilution, balancing the overall sentiment to moderately positive.

Positives

• Successful partial completion of a $5,000,000 equity financing, securing $3,000,000 in the latest tranche.
• Total capital received to date from the offering is $4,000,000, providing significant funding for company operations.
• Anticipated receipt of the remaining $1,000,000 by June 26, 2025, will fully fund the offering.
• Proceeds are earmarked for key strategic initiatives including commercialization of lead products (Spryng with OsteoCushion Technology and PrecisePRP) and financing clinical trials.

Negatives

• The offering involves the issuance of Series B Convertible Preferred Stock, which is convertible into common stock, leading to potential future dilution for existing common shareholders.
• The Subscription Agreement explicitly states that these securities are speculative, involve a high degree of risk, and immediate substantial dilution, and are not suitable for investors who cannot afford the loss of the entire investment.
• Management retains broad discretion over the application of the net proceeds, which may vary significantly from current intentions.

Risks

• **High Degree of Risk:** The investment is speculative and involves a high degree of risk, with a potential for complete loss of investment.
• **Immediate Substantial Dilution:** The Series B Convertible Preferred Stock is convertible into common stock, which will result in immediate and substantial dilution for existing common shareholders upon conversion.
• **Restricted Securities:** The Series B Preferred Stock are restricted securities under Rule 144 of the Securities Act, limiting their transferability without registration or an applicable exemption.
• **Management Discretion on Proceeds:** Management has broad discretion in the application of the net proceeds, and actual expenditures may vary from stated intentions.
• **Reliance on Accredited Investor Status:** The offering is made only to accredited investors, who must meet specific suitability standards and acknowledge the speculative nature of the investment.
• **No Impoundment/Escrow:** There is no provision for impoundment or escrow of funds, and no minimum amount required to be sold for the offering to close.
• **Reference to 10-K Risks:** Investors are advised to consider risk factors detailed in the company's Annual Report on Form 10-K for the fiscal year ended March 31, 2024, and subsequent filings.

Future Outlook

PetVivo Holdings, Inc. anticipates receiving the remaining $1,000,000 of the $5,000,000 equity financing on or before June 26, 2025. The net proceeds from this offering are intended to be primarily used for the commercialization of its lead products, Spryng with OsteoCushion Technology and PrecisePRP, to finance clinical trials, and to fund working capital and general corporate purposes. Management will have broad discretion in the application of these proceeds.

Management Comments

• The Company has duly caused this Report to be signed on its behalf by John Lai, Chief Executive Officer.

Industry Context

This equity financing will support PetVivo Holdings, Inc.'s operations within the animal health industry, specifically aiding in the commercialization of its lead products, Spryng with OsteoCushion Technology and PrecisePRP, and funding crucial clinical trials. This capital infusion is vital for companies in the animal health sector to advance product development and market penetration.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess the financing terms or company performance against global industry benchmarks.
• The offering price of $1.00 per share for the Series B Convertible Preferred Stock was arbitrarily determined by management and bears no particular relationship to the company's net worth, revenues, or any other standard criteria of value, making direct comparison to industry-standard valuations challenging based solely on this filing.

Corporate Governance

Stakeholder Impact

• **Shareholders:** Potential for future dilution due to the convertibility of Series B Preferred Stock into common stock. The capital raise provides funding for growth initiatives that could benefit long-term shareholder value.
• **Investors (Series B Preferred):** Acquire preferred stock with specific conversion rights, voting rights, liquidation preference, and a 10% annual dividend, but are subject to high investment risk and illiquidity.
• **Employees:** Continued funding for operations may provide job security and support ongoing projects.
• **Customers:** Commercialization efforts for products like Spryng and PrecisePRP may lead to increased product availability and innovation.
• **Creditors:** Improved financial liquidity from the capital raise could enhance the company's ability to meet its obligations.

Next Steps

• Receipt of the remaining $1,000,000 from the purchase option on or before June 26, 2025.
• Commercialization of lead products: Spryng with OsteoCushion Technology and PrecisePRP.
• Financing of clinical trials.
• Funding of working capital and general corporate purposes.

Key Dates

Keywords

PetVivo Holdings, PETV, Equity Financing, Series B Convertible Preferred Stock, Private Placement, Accredited Investor, SEC Filing, 8-K, Animal Health, Spryng, OsteoCushion Technology, PrecisePRP, Capital Raise, Dilution